Stay updated with breaking news from Column Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the...
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
San Diego-based biotech developer Tr1X, a company developing therapies to treat autoimmune disease, announced this morning that it has raised $75M in a Series A financing round. The funding was led by The Col
Startup TrX1 develops cell therapies that function like a particular type of regulatory T cell, or Treg, whose role includes dampening inflammation and inducing long-term tolerance. Based on research from Stanford, TrX1’s lead program is a potential therapy for preventing graft-versus-host disease.